🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

NIVO + IPI vs NIVO for MSI-H/dMMR mCRC: Health-related quality of life analysis 🔎CheckMate 8HW 👉mPFS clearly improved 👉 HRQoL, less symptoms 🧐 Supports use of Nivo IPI as 1st line treatment in MSI CRC #ESMOAmbassadors #ESMOGI25 ESMO - Eur. Oncology

🧵NEW VIDEO: Benjamin Weinberg, MD, FACP (Georgetown University) discusses promising early results from the EXPEL-PANC trial combining BXCL701 + pembrolizumab in 2nd-line advanced #PancreaticCancer Watch here ➡️tinyurl.com/2w26f5v9 Key highlights: ✅ Clinical activity observed in subset of

👏Fantastic lecture on creation of the definition of oligometastatic disease for #esophageal #cancer Dr. Hannake van Laarhoven #CancerResearch #cancer ESMO - Eur. Oncology #ESMOGI25 #ESMOAmbassadors

Dr Julien Taieb sheds light 💡 on the promise—and obstacles—of ctDNA testing. From refining assay sensitivity to integrating results into everyday clinical decisions, he emphasized improving test accuracy, accessibility, and real-world implementation. #ESMOGI25 ESMO - Eur. Oncology

This morning we spoke to Yelena Y. Janjigian MD (Memorial Sloan Kettering Cancer Center) who shared expert insights on #gastroesophagealcancer treatment at #ESMOGI25 🔬 MATTERHORN trial EFS & PRO data 🎯 Promising immunotherapy developments ⚕️ Treatment sequencing & surgical timing strategies #ESMOGI25

Listen to this week's episode of the VJOncology Podcasts featuring João Alessi, MD and Alessandro Di Federico who discussed #LungCancer updates from #ASCO25 🎧Listen here tinyurl.com/yf7f3az7 They explore the potential of new agents like tarlatamab, and dive into pivotal trials in

🚨 FDA approval alert! 🚨 #Taletrecretinib has been approved for ROS1+ advanced #NSCLC, offering a new option for patients with ROS1 fusion-positive lung cancer. 🔗 tinyurl.com/3v7vwpmr Read the full update on what this means for clinical practice ⬆️ #LCsm #LungCancer

🧪 Blood-based tests are shaking up CRC screening! #ESMOGI25 🔬 cfDNA (SHIELD, FREEDOME): sensitivity 83–91.5% 🧻 ColoSense™: 94% CRC sensitivity, FDA approved 📈 Real-world impact driven by better adherence 🧠 From FIT to futuristic—CRC screening is getting a liquid upgrade!

The OncoAlert🚨Newsletter Now Out !! Covering June 23-July 3, 2025 REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Ping VJ Oncology high5md COR2ED MEDSIR

Great catching up with Tougeron David shares key insights from #ESMOGI25 on advancing gastric & esophageal cancer care 🔬 RATIONALE-306 subgroup analysis in advanced ESCC 🎯 Biomarker-driven treatment selection strategies 📈 Most practice-changing trials from this year's

🧵 Yelena Y. Janjigian MD (Memorial Sloan Kettering Cancer Center) discusses key insights from the MATTERHORN study including updated EFS data and PROs 🔗tinyurl.com/5mu5crnx #ESMOGI25 ESMO - Eur. Oncology #GastricCancer #GCsm #GIsm OncoAlert This video is available on the GI Cancer Channel on VJOncology, which is

Expert-led Post-#ASCO2025 & #ESMOGI2025 Highlights webinars 💻📍ASCO ESMO - Eur. Oncology The #GICancer session will be chaired by Lorenza Rimassa & moderated by Dr Richard Kim, Dr Filippo Pietrantonio & Efrat Dotan MD AGENDA 👉 vjoncology.com/event/post-asc… REGISTER 👉 us06web.zoom.us/webinar/regist…

#BrunoSangro discusses #fibrolamellar HCC at #ESMOGI25. Quoting Prof Sangro “This is a call to action since #FLC is a rare disease but shouldn’t be neglected” and I cannot agree more. Post n.1. ESMO - Eur. Oncology #ESMOAmbassadors

Honored and grateful to have participated in #ESMOGI25! Huge thanks to Myriam Chalabi and Andres Cervantes for an amazing session full of great discussions and learning! 🙌✨ It was an amazing experience!

🎥Lorenza Rimassa of Humanitas University talks on the Phase III TALENTACE trial: atezo-bev + on-demand TACE improved PFS & response vs TACE alone in intermediate-stage HCC: Watch here➡️ow.ly/TYU950WlzWi ESMO - Eur. Oncology This video is available on the GI Cancer Channel on VJOncology, which

🎥Christian Singer, MD, MedUni Wien, discusses post-neoadjuvant challenges in #TNBC. For patients w/o (near-)pCR, especially non-BRCA carriers, treatment options remain limited, & more research is urgently needed. 🔗 vjoncology.com/video/ycaterae… ASCO #ASCO25 #BCSM #BreastCancer

🎥 Swati Kulkarni, MD, of Northwestern Feinberg School of Medicine highlights the PROMISE study of CE/BZA for DCIS. As a tissue-selective estrogen complex (TSEC), CE/BZA offers a novel hormonal approach: Learn more here🔗 ow.ly/lz3Q50Wme55 ASCO #ASCO25 #DCIS #BreastCancer #BCSM #CTSM #TrialUpdate

🎥 Aslaug Helland, MD, PhD, of Northwestern Feinberg School of Medicine calls for standardized methods and randomized trials to validate CTC and cfDNA use in #LungCancer. Current studies vary widely, limiting reliability and clinical impact: 🔗ow.ly/5ZG650WmegX ASCO #ASCO25 #LCSM #NSCLC